GlassScriptPhysician profile
Amy J Carter
NPI 1215302336
$7,557.48
in general payments reported to CMS, 2019-2025
36 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,102 · 2022: $1,461 · 2023: $1,552 · 2024: $1,492 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,994.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $970.26 | 2021-2025 | |
| Amgen INC. | $942.43 | 2021-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $671.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $625.90 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $609.33 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $509.07 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $503.93 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $339.47 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $337.51 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $250.56 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $185.03 | 2021-2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $140.77 | 2022-2025 | Strensiq |
| Amryt Pharma Holdings LTD | $136.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $132.74 | 2021-2024 | |
| Horizon Therapeutics Plc | $130.58 | 2022-2023 | Tepezza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.44 | 2021-2024 | Jardiance |
| Madrigal Pharmaceuticals | $116.38 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $111.94 | 2021-2024 | Farxiga |
| Abbvie INC. | $99.80 | 2021-2025 | |
| Radius Health, INC. | $82.57 | 2022-2024 | Tymlos |
| Zealand Pharma US, INC. | $79.29 | 2021-2022 | |
| Mannkind Corporation | $57.10 | 2021 | |
| Esperion Therapeutics, INC. | $56.88 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $46.20 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $40.75 | 2025 | |
| Merck Sharp & Dohme LLC | $38.98 | 2021-2023 | Steglatro, Januvia |
| Nevro Corp. | $38.37 | 2022 | |
| Ascendis Pharma Endocrinology INC | $37.77 | 2025 | Yorvipath |
| Clarus Therapeutics INC. | $24.15 | 2021 | |
| Neurocrine Biosciences, INC. | $23.69 | 2025 | |
| Beta Bionics, INC. | $22.25 | 2024 | Ilet Bionic Pancreas |
| Amarin Pharma, INC. | $18.12 | 2021 | |
| Recordati_rare_diseases_inc. | $15.79 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.88 | 2022 | |
| Roche Diabetes Care, INC. | $12.54 | 2021 | |
| Cequr Corporation | $11.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.